| Lymphoma, Follicular
Kymriah vs Tazverik
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Kymriah vs Tazverik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazverik has a higher rate of injection site reactions vs Kymriah based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazverik but not Kymriah, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kymriah
Tazverik
At A Glance
IV infusion
Single dose
CD19-directed CAR T cell therapy
Oral
Twice daily
EZH2 methyltransferase inhibitor
Indications
- Precursor Cell Lymphoblastic Leukemia Lymphoma
- Diffuse Large B-Cell Lymphoma
- Lymphoma, Follicular
- Sarcoma, Epithelioid
- Lymphoma, Follicular
Dosing
Precursor Cell Lymphoblastic Leukemia Lymphoma Single IV infusion: 0.2 to 5.0 x 10^6 CAR-positive viable T cells/kg for patients 50 kg or less; 0.1 to 2.5 x 10^8 CAR-positive viable T cells (non-weight-based) for patients above 50 kg. Infuse 2 to 14 days after lymphodepleting chemotherapy (fludarabine 30 mg/m^2 IV daily x 4 days + cyclophosphamide 500 mg/m^2 IV daily x 2 days).
Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular Single IV infusion: 0.6 to 6.0 x 10^8 CAR-positive viable T cells. Infuse 2 to 11 days (DLBCL) or 2 to 6 days (FL) after lymphodepleting chemotherapy (fludarabine 25 mg/m^2 IV daily x 3 days + cyclophosphamide 250 mg/m^2 IV daily x 3 days; bendamustine 90 mg/m^2 IV daily x 2 days as alternate).
Sarcoma, Epithelioid 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Lymphoma, Follicular 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity; select patients based on EZH2 mutation of codons Y646, A682, or A692 for EZH2-mutant R/R FL.
Contraindications
—
—
Adverse Reactions
Most common (>20%) CRS, infections-pathogen unspecified, fever, fatigue, musculoskeletal pain, headache, diarrhea, nausea, hypotension, edema, hemorrhage, hypogammaglobulinemia, viral infectious disorders, febrile neutropenia, vomiting, encephalopathy, cough, hypoxia, tachycardia, decreased appetite, acute kidney injury, dyspnea
Postmarketing Anaphylactic reaction, T cell malignancies, progressive multifocal leukoencephalopathy, blindness
Most common (>=20%) - Sarcoma, Epithelioid pain, fatigue, nausea, decreased appetite, vomiting, constipation
Most common (>=20%) - Lymphoma, Follicular fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain
Serious - Sarcoma, Epithelioid hemorrhage, pleural effusion, skin infection, dyspnea, pain, respiratory distress
Serious - Lymphoma, Follicular general physical health deterioration, abdominal pain, pneumonia, sepsis, anemia
Pharmacology
KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells; the CAR incorporates 4-1BB (CD137) and CD3 zeta intracellular signaling domains that enhance T cell expansion, persistence, and antitumor activity.
Tazemetostat is a selective inhibitor of EZH2 methyltransferase and certain gain-of-function mutations (Y646X, A682G, A692V), blocking trimethylation of histone H3 lysine 27 and relieving transcriptional repression that drives tumor growth in epithelioid sarcoma (via SWI/SNF complex dysfunction) and B-cell lymphoma with or without EZH2 mutation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kymriah
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Tazverik
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Kymriah
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tazverik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Kymriah
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Tazverik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KymriahView full Kymriah profile
TazverikView full Tazverik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.